The burden of sleep disturbances on quality of life and mental well-being in nearly 50,000 perimenopausal and postmenopausal women with and without concurrent vasomotor symptoms from the United States and Europe
Authors:
- Claudio N. SoaresCSClaudio N. Soares
- Paula BriggsPBPaula Briggs
- Carina Dinkel-KeuthageCDCarina Dinkel-Keuthage
- Nils SchoofNSNils Schoof
- Carsten MoellerCMCarsten Moeller
- Joehl NguyenJNJoehl Nguyen
- Kelly GengaKGKelly Genga
- Sheila DrakeleySDSheila Drakeley
- Kushal ModiKMKushal Modi
- Pauline M. MakiPMPauline M. Maki
Open Access
- 4 November 2025
- journal article
- Published by Wolters Kluwer Health in Menopause
- Vol. 33 (3) , 261-269
Abstract
Objectives: To quantify the burden of sleep disturbances on health-related quality of life (HRQoL) and mental well-being in perimenopausal and postmenopausal women with/without co-occurring vasomotor symptoms (VMS). Methods: Perimenopausal and postmenopausal women aged 40 to 65 years who participated in the National Health and Wellness 2019/2021 (US; N=27,621) and 2017/2020 cross-sectional surveys (France, Germany, Italy, Spain, UK; N=20,220) were included. Patient-reported outcomes were HRQoL (Short-Form Health Survey physical and mental component summary scores, EuroQol Visual Analogue Scale, EQ-5D-5L), depression (Patient Health Questionnaire-9), and anxiety (Generalized Anxiety Disorder-7 assessment). Associations between self-reported sleep disturbances and/or VMS and study outcomes were evaluated using generalized multivariable linear regression. Results: Among perimenopausal women, sleep disturbances were reported by 61.7% (US) and 60.6% (Europe) with VMS, and 38.0% (US) and 40.8% (Europe) without VMS. Among postmenopausal women, sleep disturbances were reported by 66.7% (US) and 63.4% (Europe) with VMS, and 44.5% (US) and 40.9% (Europe) without VMS. Compared with women with neither symptom, perimenopausal and postmenopausal women with sleep disturbances had worse HRQoL ( P P P P <0.001). Conclusions: Sleep disturbance was common among perimenopausal and postmenopausal women irrespective of VMS, and independently associated with negative effects on HRQoL, depression, and anxiety. Effective treatments for sleep disturbances and VMS in menopausal women are needed to mitigate the associated burden and improve well-being.Keywords
Funding Information
- Bayer
This publication has 28 references indexed in Scilit:
- Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional surveyMaturitas, 2022
- Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United StatesMaturitas, 2022
- Measurement Properties of the EQ VAS Around the Globe: A Systematic Review and Meta-Regression AnalysisValue in Health, 2021
- Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value SetsValue in Health, 2012
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- P01-141 - Vasomotor symptoms are associated with anxiety in perimenopausal womenEuropean Psychiatry, 2010
- Effects of sleep disturbance on the quality of life of Turkish menopausal women: A population-based studyMaturitas, 2009
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006
- Quality of Life in Diverse Groups of Midlife Women: Assessing the Influence of Menopause, Health Status and Psychosocial and Demographic FactorsQuality of Life Research, 2004
- Deriving a Preference-Based Single Index from the UK SF-36 Health SurveyJournal of Clinical Epidemiology, 1998